✦ LIBER ✦

Some statistical considerations for the interpretation of trials of combined androgen therapy

✍ Scribed by B. A. Blumenstein

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 709 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19931215)72:12+<3834::aid-cncr2820721714>3.0.co;2-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Statistical considerations for the inter

Statistical considerations for the interpretation of commonly utilized road traffic accident indicators: Implications for developing countries

✍ Shrikant I. Bangdiwala; Elias Anzola-Pérez; Isaac M. Glizer 📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 863 KB

Keynote address: Modulation of normal ti

Keynote address: Modulation of normal tissue toxicity by combined modality therapy: Considerations for improving the therapeutic gain

✍ F.A. Stewart 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 953 KB

Inhibition of the Akt, cyclooxygenase-2,

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer

✍ Hiroshi Miyamoto; Saleh Altuwaijri; Yi Cai; Edward M. Messing; Chawnshang Chang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract Prostate cancer cells are generally dependent on androgen stimulation mediated by the androgen receptor (AR) for growth and survival, and, therefore, hormonal manipulation, such as castration and/or the use of AR antagonists, results in a regression of the cancer. However, this treatmen

French gene therapy group reports on the

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) : Position statement from the European Society of Gene Therapy (ESGT)

📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

## Position statement from the European Society of Gene Therapy (ESGT) Background News of a serious adverse event in a clinical trial of gene therapy for inherited, X chromosome-linked Severe Combined Immunodeficiency (X-SCID) was made public on October 2, 2002, by the group of French scientists p

Report of a second serious adverse event

Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) : Position of the European Society of Gene Therapy (ESGT)

✍ Bernd Gansbacher 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr